Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 02 Sep 2022
Vertex announces U.S. FDA approval for Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis ages 12 to <24 months
2 September 2022 - With this approval, approximately 300 children with two copies of the F508del mutation will have a ...
Posted by Michael Wonder on 02 Sep 2022
FDA approves durvalumab for locally advanced or metastatic biliary tract cancer
2 September 2022 - Today the FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with gemcitabine and cisplatin for adult patients ...
Posted by Michael Wonder on 02 Sep 2022
First de novo deuterated drug poised for approval
1 September 2022 - Bristol Myers Squibb’s first in class TYK2 inhibitor and blockbuster contender deucravacitinib showcases the role for heavy ...
Posted by Michael Wonder on 02 Sep 2022
Azurity Pharmaceuticals announces FDA approval of Konvomep (omeprazole and sodium bicarbonate for oral suspension)
2 September 2022 - Azurity Pharmaceuticals announced today that the US FDA has approved Konvomep (omeprazole and sodium bicarbonate for oral ...
Posted by Michael Wonder on 02 Sep 2022
FDA approves the first treatment option for generalized pustular psoriasis flares in adults
1 September 2022 - More than half of patients treated with Spevigo (spesolimab-sbzo) injection, for intravenous use showed no visible pustules ...
Posted by Michael Wonder on 02 Sep 2022
Updated agenda for the November 2022 PBAC meeting
2 September 2022 - The agenda for the November 2022 PBAC meeting has been updated. ...
Posted by Michael Wonder on 01 Sep 2022
EMA CHMP adopts positive opinion recommending authorisation for the use of Moderna's Omicron targeting bivalent booster in the European Union
1 September 2022 - Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 sub-variants when ...
Posted by Michael Wonder on 01 Sep 2022
CADTH launches post-market drug evaluation program
1 September 2022 - CADTH is pleased to announce the launch of its new post-market drug evaluation program. ...
Posted by Michael Wonder on 01 Sep 2022
Recell System insurance coverage begins in Japan for treatment of acute burns
1 September 2022 - Reimbursement in Japan will be similar to that of pricing in the United States. ...
Posted by Michael Wonder on 01 Sep 2022
Health Canada authorises first bivalent COVID-19 booster for adults 18 years and older
1 September 2022 - Today, Health Canada authorised an adapted version of the Moderna Spikevax COVID-19 vaccine. ...
Posted by Michael Wonder on 01 Sep 2022
Vabysmo (faricimab injection) receives positive CADTH recommendation for the treatment of neovascular (wet) age-related macular degeneration in adults
1 September 2022 - Provincial jurisdictions will make the final decision on public reimbursement. ...
Posted by Michael Wonder on 01 Sep 2022
What “negotiating” with Medicare means for drug makers: a mixture of price controls and actual negotiations
1 September 2022 - In the debate on the drug pricing provisions contained in the Inflation Reduction Act, critics call the ...
Posted by Michael Wonder on 01 Sep 2022
First adapted COVID-19 booster vaccines recommended for approval in the EU
1 September 2022 - The EMA’s CHMP has recommended authorising two vaccines adapted to provide broader protection against COVID-19. ...
Posted by Michael Wonder on 01 Sep 2022
Critical kidney disease medication listed on the PBS
1 September 2022 - A life changing treatment for chronic kidney disease will be made available to thousands of Australians through ...
Posted by Michael Wonder on 01 Sep 2022
Janssen's Stelara gets insurance benefits as first-line therapy for ulcerative colitis
1 September 2022 - Janssen Korea said its ulcerative colitis Stelara (ustekinumab) won health insurance benefits as the primary treatment ...